KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Gains from Sales and Divestitures (2016 - 2025)

Ionis Pharmaceuticals (IONS) has disclosed Gains from Sales and Divestitures for 13 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 1783.56% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 1783.56%, while the annual FY2025 figure was $1.4 million, 1783.56% up from the prior year.
  • Gains from Sales and Divestitures hit $1.4 million in Q4 2025 for Ionis Pharmaceuticals, up from $73000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.4 million in Q4 2025 and bottomed at $16000.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 5 years is $670600.0, with a median of $834000.0 recorded in 2021.
  • Year-over-year, Gains from Sales and Divestitures crashed 98.08% in 2022 and then skyrocketed 6493.75% in 2023.
  • Ionis Pharmaceuticals' Gains from Sales and Divestitures stood at $834000.0 in 2021, then plummeted by 98.08% to $16000.0 in 2022, then surged by 6493.75% to $1.1 million in 2023, then plummeted by 93.08% to $73000.0 in 2024, then surged by 1783.56% to $1.4 million in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $1.4 million, $73000.0, and $1.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.